1
|
Zhou J, Meng N, Lu L, Lu J, Wu S, Ding Y, Wu S, Bao Y, Xu Q, Chen R, Wang J, Xie C, Wu J, Lu W. A novel peptide-drug conjugate for glioma-targeted drug delivery. J Control Release 2024; 369:722-733. [PMID: 38583575 DOI: 10.1016/j.jconrel.2024.04.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 04/02/2024] [Accepted: 04/04/2024] [Indexed: 04/09/2024]
Abstract
The existence of the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) greatly limits the application of chemotherapy in glioma. To address this challenge, an optimal drug delivery system must efficiently cross the BBB/BBTB and specifically deliver therapeutic drugs into glioma cells while minimizing systemic toxicity. Here we demonstrated that glucose-regulated protein 78 (GRP78) and dopamine receptor D2 were highly expressed in patient-derived glioma tissues, and dopamine receptors were highly expressed on the BBB. Subsequently, we synthesized a novel "Y"-shaped peptide and compared the effects of different linkers on the receptor affinity and targeting ability of the peptide. A peptide-drug conjugate (pHA-AOHX-VAP-doxorubicin conjugate, pHA-AOHX-VAP-DOX) with a better affinity for glioma cells and higher solubility was derived for glioma treatment. pHA-AOHX-VAP-DOX could cross both BBB and BBTB via dopamine receptor and GRP78 receptor, and finally target glioma cells, significantly prolonging the survival time of nude mice bearing intracranial glioma. Furthermore, pHA-AOHX-VAP-DOX significantly reduced the toxicity of DOX and increased the maximum tolerated dose (MTD). Collectively, this work paves a new avenue for overcoming multiple barriers and effectively delivering chemotherapeutic agents to glioma cells while providing key evidence to identify potential receptors for glioma-targeted drug delivery.
Collapse
Affiliation(s)
- Jianfen Zhou
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Nana Meng
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Linwei Lu
- Department of Integrative Medicine, Huashan Hospital, Fudan University, and Institutes of Integrative Medicine of Fudan University, Shanghai 200040, China
| | - Jiasheng Lu
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Sunyi Wu
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Yuan Ding
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Shuai Wu
- Glioma Surgery Division, Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
| | - Yanning Bao
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Qianzhu Xu
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Ruohan Chen
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Jun Wang
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Cao Xie
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China
| | - Jinsong Wu
- Glioma Surgery Division, Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
| | - Weiyue Lu
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, Shanghai 201203, China; Shanghai Engineering Technology Research Center for Pharmaceutical Intelligent Equipment, and Shanghai Frontiers Science Center for Druggability of Cardiovascular non-coding RNA, Institute for Frontier Medical Technology, Shanghai University of Engineering Science, Shanghai 201620, China.
| |
Collapse
|
2
|
Yuan Y, Wang W, Luo J, Tang C, Zheng Y, Yu J, Xu H, Zhu M, Hang T, Wang H, Diao X. Metabolite characterisation of the peptide-drug conjugate LN005 in liver S9s by UHPLC-Orbitrap-HRMS. Xenobiotica 2024; 54:1-9. [PMID: 38044881 DOI: 10.1080/00498254.2023.2289635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Accepted: 11/27/2023] [Indexed: 12/05/2023]
Abstract
LN005 is a peptide-drug conjugate (PDC) targeting glucose-regulated protein 78 (GRP78) to treat several types of cancer, such as breast, colon, and prostate cancer.As a new drug modality, understanding its metabolism and elimination pathways will help us to have a whole picture of it. Currently, there are no metabolic studies on LN005; therefore, this study aimed to investigate the metabolism of LN005, clarify its metabolic profile in the liver S9s of different species, and identify the major metabolic pathways and differences between species.The incubation samples were measured by ultra-high performance liquid chromatography combined with orbitrap tandem mass spectrometry (UHPLC-Orbitrap-HRMS).The results showed that LN005 was metabolised by liver S9s, and four metabolites were identified. The main metabolic pathway of LN005 in liver S9s was oxidative deamination to ketone or hydrolysis. Similar metabolic profiles were observed in mouse, rat, dog, monkey, and human liver S9s, indicating no differences between these four animal species and humans.This study provides information for the structural modification and optimisation of LN005 and affords a reference for subsequent animal experiments and human metabolism of other PDCs.
Collapse
Affiliation(s)
- Yali Yuan
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Weiqiang Wang
- Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China
| | - Jing Luo
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
- Department of Preparation, Shanghai Whittlong Pharmaceutical Institute Co., Ltd, Shanghai, China
| | - Chongzhuang Tang
- Department of Biotransformation, XenoFinder Co., Ltd, Suzhou, China
| | - Yuandong Zheng
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Jinghua Yu
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Honghong Xu
- Department of Preparation, Shanghai Whittlong Pharmaceutical Institute Co., Ltd, Shanghai, China
| | - Mingshe Zhu
- Department of Biotransformation, XenoFinder Co., Ltd, Suzhou, China
| | - Taijun Hang
- Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China
| | - Hao Wang
- National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Xingxing Diao
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| |
Collapse
|
3
|
Wu S, Lu L, Zhou J, Ran D, Wang S, Xu Q, Xu W, Wang J, Liu Y, Xie C, Luo Z, Lu W. All-stage targeted therapy for glioblastoma based on lipid membrane coated cabazitaxel nanocrystals. J Control Release 2022; 345:685-695. [PMID: 35346767 DOI: 10.1016/j.jconrel.2022.03.047] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Revised: 03/21/2022] [Accepted: 03/23/2022] [Indexed: 01/14/2023]
Abstract
Glioblastoma (GBM) is the most aggressive brain tumor with poor prognosis and frequent recurrence. The blood-brain barrier (BBB), blood-brain tumor barrier (BBTB) hinder the entry of therapeutics into the glioma region. Vasculogenic mimicry (VM) formed by invasive glioma cells is also related to recurrence of GBM. VAP is a D-peptide ligand of GRP78 protein overexpressed on BBTB, VM, and glioma cells but not on normal tissues. Besides, p-hydroxybenzoic acid (pHA) can effectively traverse the BBB. Herein we developed an all-stage glioma-targeted cabazitaxel (CBZ) nanocrystal loaded liposome modified with a "Y" shaped targeting ligand composed of pHA and VAP (pV-Lip/cNC). The pure drug nanocrystal core provided high drug loading, while lipid membrane promoted the stability and circulation time. pV-Lip/cNC exhibited excellent glioma homing, barriers crossing, and tumor spheroid penetrating capability in vitro. Treatment of pV-Lip/cNC displayed enhanced CBZ accumulation in glioma and anti-glioma effect with a median survival time (53 days) significantly longer than that of cNC loaded liposomes modified with either single ligand (42 days for VAP and 45 days for pHA) in the murine orthotopic GBM model. These results indicated pV-Lip/cNC could traverse the BBB and BBTB, destruct VM, and finally kill glioma cells to realize all-stage glioma therapy.
Collapse
Affiliation(s)
- Sunyi Wu
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
| | - Linwei Lu
- The Department of Integrative Medicine, Huashan Hospital, Fudan University, and The Institutes of Integrative Medicine of Fudan University, Shanghai 200040, China
| | - Jianfen Zhou
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
| | - Danni Ran
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
| | - Songli Wang
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
| | - Qianzhu Xu
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
| | - Weixia Xu
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
| | - Jun Wang
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
| | - Yu Liu
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
| | - Cao Xie
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
| | - Zimiao Luo
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China.
| | - Weiyue Lu
- Department of Pharmaceutics, School of Pharmacy, & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education and PLA, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China; The Department of Integrative Medicine, Huashan Hospital, Fudan University, and The Institutes of Integrative Medicine of Fudan University, Shanghai 200040, China; Shanghai Engineering Technology Research Center for Pharmaceutical Intelligent Equipment, and Shanghai Frontiers Science Center for Druggability of Cardiovascular non-coding RNA, Institute for Frontier Medical Technology, Shanghai University of Engineering Science, Shanghai 201620, China; Minhang Branch, Zhongshan Hospital and Institute of Fudan-Minghang Academic Health System, Minghang Hospital, Fudan University, Shanghai 201199, China.
| |
Collapse
|
4
|
Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma. Eur J Med Chem 2021; 230:114093. [PMID: 35007860 DOI: 10.1016/j.ejmech.2021.114093] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 12/23/2021] [Accepted: 12/26/2021] [Indexed: 12/30/2022]
Abstract
A type of pH-sensitive multi-targeted brain tumor site-specific liposomes (Lip-CTPP) co-modified with p-hydroxybenzoic acid (p-HA) and triphenylphosphonium (TPP) were designed and prepared to co-load doxorubicin (DOX) and lonidamine (LND). Lip-CTPP are promising potential carriers to exert the anti-glioma effect of DOX and LND collaboratively given the following features: 1) Lip-CTPP have a good pharmacokinetic behavior; 2) Lip-CTPP can cross the blood-brain barrier (BBB) and recognize tumor cells through the affinity of p-HA and dopamine/sigma receptors; 3) Lip-CTPP are highly positive charged once the acid-sensitive amide bonds are cleaved in endo/lysosomes to expose TPP and protonate amine groups; 4) the positive charged Lip-CTPP escape from endo/lysosomes and accumulate in mitochondria through electrostatic adsorption; 5) DOX and LND are released and synergistically increase anti-tumor efficacy. Our in vitro and in vivo results confirmed that Lip-CTPP could greatly elevate the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function. In addition, Lip-CTPP could significantly prolong the survival time of glioma bearing mice, narrow the tumor region and inhibit the infiltration and metastasis capability of glioma cells. Collectively, Lip-CTPP are promising nano formulations to enhance the synergistic effect of DOX and LND in glioma treatment.
Collapse
|
5
|
Guo H, Wang R, Wang D, Wang S, Zhou J, Chai Z, Yao S, Li J, Lu L, Liu Y, Xie C, Lu W. Deliver anti-PD-L1 into brain by p-hydroxybenzoic acid to enhance immunotherapeutic effect for glioblastoma. J Control Release 2020; 320:63-72. [DOI: 10.1016/j.jconrel.2020.01.005] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 12/31/2019] [Accepted: 01/04/2020] [Indexed: 12/11/2022]
|
6
|
De Los Reyes-Berbel E, Salto-Gonzalez R, Ortega-Muñoz M, Reche-Perez FJ, Jodar-Reyes AB, Hernandez-Mateo F, Giron-Gonzalez MD, Santoyo-Gonzalez F. PEI-NIR Heptamethine Cyanine Nanotheranostics for Tumor Targeted Gene Delivery. Bioconjug Chem 2018; 29:2561-2575. [PMID: 29953208 DOI: 10.1021/acs.bioconjchem.8b00262] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Polymer-based nanotheranostics are appealing tools for cancer treatment and diagnosis in the fast-growing field of nanomedicine. A straightforward preparation of novel engineered PEI-based nanotheranostics incorporating NIR fluorescence heptamethine cyanine dyes (NIRF-HC) to enable them with tumor targeted gene delivery capabilities is reported. Branched PEI-2 kDa (b2kPEI) is conjugated with IR-780 and IR-783 dyes by both covalent and noncovalent simple preparative methodologies varying their stoichiometry ratio. The as-prepared set of PEI-NIR-HC nanocarriers are assayed in vitro and in vivo to evaluate their gene transfection efficiency, cellular uptake, cytotoxicity, internalization and trafficking mechanisms, subcellular distribution, and tumor specific gene delivery. The results show the validity of the approach particularly for one of the covalent IR783-b2kPEI conjugates that exhibit an enhanced tumor uptake, probably mediated by organic anion transporting peptides, and favorable intracellular transport to the nucleus. The compound behaves as an efficient nanotheranostic transfection agent in NSG mice bearing melanoma G361 xenographs with concomitant imaging signal and gene concentration in the targeted tumor. By this way, advanced nanotheranostics with multifunctional capabilities (gene delivery, tumor-specific targeting, and NIR fluorescence imaging) are generated in which the NIRF-HC dye component accounts for simultaneous targeting and diagnostics, avoiding additional incorporation of additional tumor-specific targeting bioligands.
Collapse
Affiliation(s)
- Eduardo De Los Reyes-Berbel
- Department of Organic Chemistry, Biotechnology Institute, Faculty of Sciences , University of Granada , 18071 Granada , Spain
| | - Rafael Salto-Gonzalez
- Department of Biochemistry and Molecular Biology II, School of Pharmacy , University of Granada , 18071 Granada , Spain
| | - Mariano Ortega-Muñoz
- Department of Organic Chemistry, Biotechnology Institute, Faculty of Sciences , University of Granada , 18071 Granada , Spain
| | - Francisco Jose Reche-Perez
- Department of Biochemistry and Molecular Biology II, School of Pharmacy , University of Granada , 18071 Granada , Spain
| | - Ana Belen Jodar-Reyes
- Biocolloid and Fluid Physics Group, Department of Applied Physics, Faculty of Sciences , University of Granada , 18071 Granada , Spain
| | - Fernando Hernandez-Mateo
- Department of Organic Chemistry, Biotechnology Institute, Faculty of Sciences , University of Granada , 18071 Granada , Spain
| | - Maria Dolores Giron-Gonzalez
- Department of Biochemistry and Molecular Biology II, School of Pharmacy , University of Granada , 18071 Granada , Spain
| | - Francisco Santoyo-Gonzalez
- Department of Organic Chemistry, Biotechnology Institute, Faculty of Sciences , University of Granada , 18071 Granada , Spain
| |
Collapse
|
7
|
Curcumin Loaded Fe3O4 Nanoparticles: An MRI Contrast Agent to Investigate the Impact of Curcumin on Maximizing Negative Contrast and r2 Relaxation Rate. J Inorg Organomet Polym Mater 2018. [DOI: 10.1007/s10904-018-0868-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
8
|
Aeineh N, Salehi F, Akrami M, Nemati F, Alipour M, Ghorbani M, Nikfar B, Salehian F, Riyahi Alam N, Sadat Ebrahimi SE, Foroumadi A, Khoobi M, Rouini M, Dibaei M, Haririan I, Ganjali MR, Safaei S. Glutathione conjugated polyethylenimine on the surface of Fe 3O 4 magnetic nanoparticles as a theranostic agent for targeted and controlled curcumin delivery. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION 2018; 29:1109-1125. [PMID: 29320951 DOI: 10.1080/09205063.2018.1427013] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Theranostics with the ability to simultaneous monitoring of treatment progress and controlled delivery of therapeutic agents has become as an emerging therapeutic paradigm in cancer therapy. In this study, we have developed a novel surface functionalized iron oxide nanoparticle using polyethyleneimine and glutathione for targeted curcumin (CUR) delivery and acceptable pH sensitive character. The developed magnetic nanoparticles (MNPs) were physicochemically characterized by FT-IR, XRD, FE-SEM and TEM. The MNPs was obtained in spherical shape with diameter of 50 nm. CUR was efficiently loaded into the MNPs and then in vitro release analyses were evaluated and showed that the prepared MNPs could release higher amount of CUR in acidic medium compared to neutral medium due to the pH sensitive property of the coated polymer. MTT assay confirmed the superior toxicity of CUR loaded MNPs compared to the control nanoparticles. Higher cellular uptake of the MNPs than negative control cells was demonstrated in SK-N-MC cell line. In vitro assessment of MRI properties showed that synthesized MNPs could be used as MRI imaging agent. Furthermore, according to hemolysis assay, the developed formulation exhibited suitable hemocompatibility. In vivo blood circulation analysis of the MNPs also exhibited enhanced serum bioavailability up to 2.5 fold for CUR loaded MNPs compared with free CUR.
Collapse
Affiliation(s)
- Navid Aeineh
- a Department of Chemistry , Semnan University , Semnan , Iran
| | - Fahimeh Salehi
- b Institute of Biochemistry and Biophysics, Department of Biochemistry , University of Tehran , Tehran , Iran
| | - Mohammad Akrami
- c Department of Pharmaceutics, and Department of Pharmaceutical Biomaterials & Medical Biomaterials Research Center, Faculty of Pharmacy , Tehran University of Medical Sciences , Tehran , Iran
| | - Firouzeh Nemati
- a Department of Chemistry , Semnan University , Semnan , Iran
| | - Masoumeh Alipour
- d Nanobiomaterials Group, Pharmaceutical Sciences Research Center , Tehran University of Medical Sciences , Tehran , Iran
| | - Milad Ghorbani
- d Nanobiomaterials Group, Pharmaceutical Sciences Research Center , Tehran University of Medical Sciences , Tehran , Iran
| | - Banafsheh Nikfar
- e Medical Physics and Biomedical Engineering Department, School of Medicine , Tehran University of Medical Sciences , Tehran , Iran
| | - Fatemeh Salehian
- c Department of Pharmaceutics, and Department of Pharmaceutical Biomaterials & Medical Biomaterials Research Center, Faculty of Pharmacy , Tehran University of Medical Sciences , Tehran , Iran
| | - Nader Riyahi Alam
- e Medical Physics and Biomedical Engineering Department, School of Medicine , Tehran University of Medical Sciences , Tehran , Iran
| | - Seyed Esmaeil Sadat Ebrahimi
- f Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center , Tehran University of Medical Sciences , Tehran , Iran
| | - Alireza Foroumadi
- f Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center , Tehran University of Medical Sciences , Tehran , Iran
| | - Mehdi Khoobi
- c Department of Pharmaceutics, and Department of Pharmaceutical Biomaterials & Medical Biomaterials Research Center, Faculty of Pharmacy , Tehran University of Medical Sciences , Tehran , Iran.,d Nanobiomaterials Group, Pharmaceutical Sciences Research Center , Tehran University of Medical Sciences , Tehran , Iran
| | - Mohammadreza Rouini
- g Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Sciences , Tehran , Iran
| | - Maryam Dibaei
- g Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Sciences , Tehran , Iran
| | - Ismaeil Haririan
- c Department of Pharmaceutics, and Department of Pharmaceutical Biomaterials & Medical Biomaterials Research Center, Faculty of Pharmacy , Tehran University of Medical Sciences , Tehran , Iran
| | - Mohammad Reza Ganjali
- h Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute , Tehran University of Medical Sciences , Tehran , Iran.,i Center of Excellence in Electrochemistry, Faculty of Chemistry , University of Tehran , Tehran , Iran
| | - Saeed Safaei
- j Imam Khomeini Imaging Center , Iran University of Medical Sciences , Tehran , Iran
| |
Collapse
|
9
|
Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery. J Control Release 2017; 255:132-141. [DOI: 10.1016/j.jconrel.2017.04.006] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 03/27/2017] [Accepted: 04/05/2017] [Indexed: 12/29/2022]
|
10
|
GRP78 enabled micelle-based glioma targeted drug delivery. J Control Release 2017; 255:120-131. [DOI: 10.1016/j.jconrel.2017.03.037] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2016] [Revised: 03/15/2017] [Accepted: 03/20/2017] [Indexed: 01/01/2023]
|
11
|
Brain-Targeted Polymers for Gene Delivery in the Treatment of Brain Diseases. Top Curr Chem (Cham) 2017; 375:48. [PMID: 28397188 DOI: 10.1007/s41061-017-0138-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Accepted: 03/27/2017] [Indexed: 10/19/2022]
Abstract
Gene therapies have become a promising strategy for treating neurological disorders, such as brain cancer and neurodegenerative diseases, with the help of molecular biology interpreting the underlying pathological mechanisms. Successful cellular manipulation against these diseases requires efficient delivery of nucleic acids into brain and further into specific neurons or cancer cells. Compared with viral vectors, non-viral polymeric carriers provide a safer and more flexible way of gene delivery, although suffering from significantly lower transfection efficiency. Researchers have been devoted to solving this defect, which is attributed to the multiple barriers existing for gene therapeutics in vivo, such as systemic degradation, blood-brain barrier, and endosome trapping. This review will be mainly focused on systemically administrated brain-targeted polymers developed so far, including PEI, dendrimers, and synthetic polymers with various functions. We will discuss in detail how they are designed to overcome these barriers and how they efficiently deliver therapeutic nucleic acids into targeted cells.
Collapse
|
12
|
Shen J, Yu M, Meng Q, Li J, Lv Y, Lu W. Fatty Acid-Based Strategy for Efficient Brain Targeted Gene Delivery. Pharm Res 2013; 30:2573-83. [DOI: 10.1007/s11095-013-1056-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2012] [Accepted: 04/04/2013] [Indexed: 11/24/2022]
|
13
|
p-Hydroxybenzoic acid (p-HA) modified polymeric micelles for brain-targeted docetaxel delivery. ACTA ACUST UNITED AC 2013. [DOI: 10.1007/s11434-013-5760-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|